TRIPLE NEGATIVE BREAST CANCER

This study is testing whether some patients with early-stage breast cancer who have an exceptional response to chemotherapy can safely avoid surgery. It aims to see if a non-surgical approach leads to similar cancer control as the standard surgery. The trial will enroll 84 patien…

This early-stage study is testing a new type of personalized immune cell therapy called GCAR1 in people with advanced cancers that have stopped responding to standard treatments. The main goal is to find the safest and most effective dose of GCAR1 for patients with specific types…

This large, late-stage trial aims to see if adding the drug pembrolizumab to standard follow-up treatment helps prevent cancer from coming back in people with early triple-negative breast cancer. It will enroll 1,000 patients whose cancer did not completely disappear after initia…

This study tests an experimental drug called ARX788 for people with advanced HER2-low breast cancer that has spread or cannot be surgically removed. The drug is designed to deliver a cancer-killing toxin directly to tumor cells. Researchers will measure how well tumors shrink, ho…

This trial is testing a new combination of three drugs as the first treatment for people with advanced triple-negative breast cancer that tests positive for a marker called PD-L1. The goal is to see if the combination is safe and can shrink tumors and control the cancer. It will …

This study is for women with a specific, aggressive type of early-stage breast cancer (triple-negative). It tests if patients whose cancer disappears completely after powerful drug treatment can safely skip the standard follow-up surgery. The goal is to see if avoiding surgery pr…

This study is testing whether personalized dosing guidelines for people with a specific blood type (Duffy null) can help them better tolerate standard cancer treatments. Researchers will enroll 90 people with multiple myeloma or triple-negative breast cancer to see if these tailo…

This study is testing whether adding a new immunotherapy drug (serplulimab) to standard chemotherapy before surgery helps shrink tumors more effectively in people with triple-negative breast cancer. It will involve about 46 women with early-stage disease to see if this combinatio…

This study is testing if injecting a common local anesthetic (levobupivacaine) around the tumor and nearby nerves before breast-conserving surgery can help prevent the cancer from coming back. It will involve 760 women with triple-negative breast cancer, a type known for a higher…

This is the first study in people to test a new drug called ITC-6146RO for patients with advanced or metastatic cancer who have run out of standard treatment options. The main goals are to find a safe dose and see how the body processes the drug. The study will enroll about 102 a…

This early-stage trial will test the safety and feasibility of a personalized cancer vaccine for people newly diagnosed with triple negative breast cancer. The vaccine is custom-made for each patient based on their tumor. Researchers will also test if adding an experimental immun…

This study aims to find better treatments for advanced breast cancer by matching therapies to specific tumor characteristics. It will enroll 700 patients whose cancer has progressed after initial treatment. Doctors will analyze tumor markers and assign standard treatments accordi…

This study is testing whether a three-drug combination can help control triple-negative breast cancer that has worsened despite previous immunotherapy. It will enroll 46 women whose cancer has progressed after standard treatments. The approach adds a mast cell stabilizer (cromoly…

This study is testing if freezing a breast tumor (cryoablation) combined with an immunotherapy drug (pembrolizumab) can better train the body's immune system to fight triple-negative breast cancer. It will compare this new approach to standard treatment and freezing alone in 36 w…

This large trial is testing two main ideas for treating aggressive, early-stage triple-negative breast cancer. First, it asks if patients who respond very well to initial chemo can safely skip more of it and go straight to surgery. Second, for patients who don't respond as well, …

This study is testing a new artificial intelligence (AI) tool designed to help doctors treat triple-negative breast cancer. The tool analyzes images of a patient's tumor tissue to predict how well they might respond to chemotherapy and their chances of survival. The research will…

This study aims to learn if a highly sensitive blood test can detect tiny traces of cancer DNA in patients with early-stage triple negative breast cancer. Researchers will collect blood from 77 participants at diagnosis and during their treatment to see if the test can find cance…

This study is testing whether a new blood test can detect if triple-negative breast cancer is returning earlier than current standard scans. Thirty patients who have finished initial treatment will be randomly assigned to receive either standard follow-up care or standard care pl…